We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+9.98%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$846M
AUM Growth
-$143M
Cap. Flow
-$121M
Cap. Flow %
-14.33%
Top 10 Hldgs %
70.39%
Holding
52
New
24
Increased
5
Reduced
10
Closed
6

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$47.4M
2
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$36.8M
3
TGTX icon
TG Therapeutics
TGTX
+$19.2M
4
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$18.7M
5
LRMR icon
Larimar Therapeutics
LRMR
+$13.8M

Top Sells

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$147M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$51.4M
3
RPRX
Repros Therapeutics Inc.
RPRX
+$21.1M
4
DYAX
DYAX CORPORATION
DYAX
+$21.1M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$20.5M

Sector Composition

Rank Sector Weight
1 Healthcare 49.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
1
CALL
Acadia Pharmaceuticals
ACAD
$4.51B
$130M 15.36%
5,250,000
– –
DYAX
2
DELISTED
DYAX CORPORATION
DYAX
$79M 9.34%
7,809,139
-2,173,439
-22% -$21.1M
BCRX icon
3
BioCryst Pharmaceuticals
BCRX
$2.42B
$69.1M 8.17%
7,069,159
+3,870,630
+121% +$47.4M
ACHN
4
DELISTED
Achillion Pharmaceuticals
ACHN
$66.9M 7.9%
6,700,000
-15,786,007
-70% -$147M
SGMO
5
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$64.7M 7.65%
6,000,000
– –
AVNR
6
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$64.2M 7.59%
+5,386,700
New +$36.8M
VIRX
7
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$34.8M 4.11%
23,187
– –
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$30.9M 3.65%
2,428,571
– –
ACHN
9
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$29.9M 3.54%
3,000,000
– –
BLUE
10
DELISTED
bluebird bio
BLUE
$26.1M 3.09%
56,264
+17,428
+45% +$8.04M
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$22.9M 2.71%
588,941
+61,000
+12% +$2.39M
ZSPH
12
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$22.1M 2.62%
+564,483
New +$18.7M
TGTX icon
13
TG Therapeutics
TGTX
$8.19B
$22M 2.6%
+2,065,571
New +$19.2M
NVAX icon
14
Novavax
NVAX
$1.21B
$21.1M 2.5%
253,354
-79,733
-24% -$7.21M
DVAX
15
DELISTED
Dynavax Technologies
DVAX
$17.4M 2.06%
1,217,900
-185,759
-13% -$2.68M
ARAV
16
DELISTED
Aravive, Inc. Common Stock
ARAV
$17.1M 2.02%
149,832
-50,668
-25% -$6.71M
TXMD icon
17
TherapeuticsMD
TXMD
$23.8M
$16M 1.89%
69,087
-16,974
-20% -$4.28M
LRMR icon
18
Larimar Therapeutics
LRMR
$377M
$14.4M 1.7%
+61,080
New +$13.8M
AKBA icon
19
Akebia Therapeutics
AKBA
$338M
$13.2M 1.56%
597,363
– –
SGMO
20
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$13.2M 1.56%
1,220,209
-1,571,096
-56% -$20.5M
XNCR icon
21
Xencor
XNCR
$1.45B
$11.6M 1.37%
1,248,923
+232,188
+23% +$2.35M
ENTA icon
22
Enanta Pharmaceuticals
ENTA
$362M
$9.89M 1.17%
250,000
-1,289,586
-84% -$51.4M
TENX icon
23
Tenax Therapeutics
TENX
$393M
$9.18M 1.09%
73
+63
+630% +$8.09M
SCYX icon
24
SCYNEXIS
SCYX
$37.4M
$6.21M 0.73%
10,500
– –
FRTX
25
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$6.13M 0.72%
+1,738
New +$6.75M
1
2 3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, RA Capital Management held 52 positions worth $846M, down 14% from $989M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

RA Capital Management withdrew a net $121M in Q3 2014, closing 6 positions and reducing 10 holdings. Its most notable exit was Repros Therapeutics Inc., an estimated $21.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 60% a quarter earlier.

Against the trend, RA Capital Management opened a new position in AVANIR PHARMACEUTICALS, INC CL A worth $64.2M.

  • RA Capital Management's largest Q3 2014 buy was AVANIR PHARMACEUTICALS, INC CL A: 5,386,700 shares worth $64.2M.
  • RA Capital Management added most to BioCryst Pharmaceuticals in Q3 2014, an estimated $47.4M increase.
  • RA Capital Management's biggest Q3 2014 reduction was Achillion Pharmaceuticals, cutting an estimated $147M.
  • RA Capital Management fully exited Repros Therapeutics Inc. in Q3 2014, selling an estimated $21.1M.
  • RA Capital Management's ten largest holdings make up 70% of its $846M portfolio in Q3 2014.
  • RA Capital Management opened 24 new positions and closed 6 in Q3 2014.
  • RA Capital Management's portfolio value fell 14% quarter-over-quarter to $846M.

Based on RA Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.